Risky Biotech Stocks’ Recovery Hinges on Deeper Fed Rate Cuts

The prospect of further interest-rate cuts from the Federal Reserve is finally giving diehard believers in the biotechnology sector reason for guarded optimism after a punishing four years....

Redirecting to full article...